Primary and secondary prevention of sudden cardiac death in a hospital of the social security system in Costa Rica: report from the registry of patients with implantable cardioverter- defibrillators, 2007-2011
DOI:
https://doi.org/10.51481/amc.v55i1.782Keywords:
Implantable defibrillators, sudden death, arrhythmiasAbstract
Aim: Several studies have demonstrated the efficacy of implantable cardioverter-defibrillators in the prevention of sudden cardiac death. The validation of this evidence has to be assessed through various registries. The objective of this study was to describe the main epidemiological and clinical characteristics of patients who were referred to a tertiary hospital in Costa Rica to be treated with a cardioverter-defibrillators implantable; as well as the associated problems and complications.
Methods: A retrospective observational cohort study, which included all patients who were treated with a cardioverter-defibrillator implantable in the ""Dr. Rafael A. Calderón Guardia"" hospital between 2007 and 2011.
Results: Twenty three patients were included. The mean age was 55 ± 18 years. Ischemic heart disease was the most frequent etiology (10 patients). Twenty patients had functional class I or II and the mean ejection fraction was 0.38 ± 0.17. In 18 patients, the cardioverter-defibrillator was implanted for secondary prevention. Five patients had an early complication; all of them had dual-chamber devices: 2 minor hematomas, 1 coronary sinus dissection, 1 right atrial lead displacement, and 1 cardio embolic stroke. From a total of 101 therapies (in 8 patients), 94 were appropriate (in 5 patients) and 7 were inappropriate (in 3 patients); 2 of the latter 3 patients had a history of atrial fibrillation episodes.
Conclusion: This registry shows that the majority of implantable cardioverter-defibrillators implantations are performed as a secondary prevention, with a high rate of adequate therapies and a low rate of inadequate ones. The registry allowed an assessment of the indications and complications of this device therapy.
Downloads
References
Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000; 36: 2212-8.
Kuller L, Lilienfeld A, Fisher R. An epidemiological study of sudden and unexpected deaths in adults. Medicine (Baltimore) 1967; 46:341-361.
Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001; 345: 1473-82.
The MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
The Multicentre Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309: 331- 6.
Bigger JT Jr., Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984; 69:250-8.
Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989; 80:1675-80.
The antiarrhythmics versus implantable defibrillator (AVID) investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-1583.
Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/ AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Circulation. 2008; 117:2820-2840.
Hammill SC, Berul C, Kremers MS, Kadish AH, Stevenson LW, Heidenreich PA, et al. Review of the ICD Registry's Third Year, Expansion to include Lead Data and Pediatric ICD Procedures, and Role for Measuring Performance. Heart Rhythm (2009); 6: 1397-1401.
Di toro D, Boracci RA, Rubio M, Serra J. Estimación del número de marcapasos y cardiodesfibriladores implantados anualmente en Argentina. Rev Argent Cirugía. 2009; 97: 85-90.
Proclemer A, Ghidina M, Cicuttini G, Gregori D, Fioretti PM: Impact of the Main Implantable Cardioverter-Defibrillator Trials for Primary and Secondary Prevention in Italy: A Survey of the National Activity During the Years 2001-2004. PACE 2006; 29 (Suppl 2): S20-S28.
Dubner S, Valero E, Pesce R, Zuelgaray JG, Mateos JC, Filho SG, Reyes W et al. A Latin American registry of implantable cardioverter de- fibrillators: the ICD-LABOR study. Ann Noninvasive Electrocardiol. 2005; 10: 420-8.
Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000; 21: 2071- 8.
Gutiérrez O, Garita E, Salazar E. Thoracoscopic Sympathectomy For Incessant Polymorphic Ventricular Tachycardia In Chronic Chagasic Myocarditis. A Case Report. Int J Cardiol 2007 Jul 10;119: 255-7.
Epstein AE, DiMarco JP, Ellenbogen KA, Mark Estes NA, Freedman
RA , Gettes LS et al. ACC/AHA/HRS 2008 Guidelines for DeviceBased Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of
Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117; 350-408.
Myerburg RJ, Reddy V, Castellanos A. Indications for implantable cardioverter- defibrillators based on evidence and judgment. J Am Coll Cardiol. 2009; Vol. 54: 747-63.
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineu R, Domanski M, et al. Amiodarone or an implantable cardioverterdefibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.
Borleffs CJW, van Rees JB, van Welsenes GH, van der Velde ET, van Erven L, Bax JJ, et al. Prognostic Importance of Atrial Fibrillation in Implantable Cardioverter-Defibrillator Patients. J Am Coll Cardiol 2010;55:879-85
Van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L. Implantation-Related Complications of Implantable
Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Devices. A Systematic Review of Randomized Clinical Trials. J Am Coll Cardiol 2011; 58:995-1000
Theuns DA, Klootwijk AP, Goedhart DM, Jordaens LJ.
Prevention of Inappropriate Therapy in Implantable CardioverterDefibrillators: Results of a Prospective, Randomized Study of Tachyarrhythmia Detection Algorithms. J Am Coll Cardiol 2004;44:2362-7
Lee DS, Krahn AD, Healey JS, Birnie D, Crystal E, Dorian P, et al for the Investigators of the Ontario ICD Database. Evaluation of Early Complications Related to De Novo Cardioverter Defibrillator Implantation Insights From the Ontario ICD Database. J Am Coll Cardiol 2010; 55:774-82.
Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD. Dual-Chamber Implantable Cardioverter-Defibrillator Selection Is Associated With Increased Complication Rates and Mortality Among Patients Enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. J Am Coll Cardiol 2011; 58:1007-13.
Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD, et al. The Frequency and Incremental Cost of Major Complications Among Medicare Beneficiaries Receiving Implantable Cardioverter-Defibrillators. J Am Coll Cardiol 2006; 47:2493-7.
Van Rees JB, Willem Borleffs CJ, de Bie MK, Stijnen T, van Erven
L, Bax JJ, Schalij MJ. Inappropriate Implantable CardioverterDefibrillator Shocks: Incidence, Predictors and Impact on Mortality. J Am Coll Cardiol 2011;57:556-62
Hohnloser SH, Al-Khalidi HR, Pratt CM, et al. Electrical storm in patients with implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial. Eur Heart J 2006; 27:3027-32.
Gasparini M, Lunati M, Landolina M, Santini M, Padeletti
L, Perego G, et al on behalf of the InSync ICD Italian Registry Investigators. Electrical storm in patients with biventricular implantable cardioverter defibrillator: Incidence, predictors, and prognostic implications. Am Heart J 2008; 156:847-54.
Connolly SJ, Dorian P, Roberts RS, et al. Comparison of b-blockers, amiodarone plus b-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators. The OPTIC study: a randomized trial. JAMA 2006; 295:165-71.
Downloads
Published
Versions
- 2013-01-01 (2)
- 2013-04-05 (1)
Issue
Section
License
Copyright (c) 2013 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
